Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.
Primary treatment with I-125 seeds or HDR-BT
No previous treatment for prostate cancer
Age ≥ 18 years
HDR- or PDR-BT
Pre-existent auto-immune disease
patients under bloodthinning medication
substance abuse
Prostate cancer patients planning to undergo sole brachytherapy treatment
Other
Prospective
Not listed
Longitudinal changes of peripheral immune cells and cell-free DNA and tumor-associated tissue in patients with prostate cancer treated with brachytherapy
Longitudinal changes of peripheral immune cells and cell-free DNA and tumor-associated tissue in patients with prostate cancer treated with brachytherapy in the primary as well as in the recurrent setting.
Treatment-related toxicity
Acute toxicity related to brachytherapy
recurrence-free survival
recurrence-free survival
Overall survival
Overall survival
Click on the lead sponsor to view all of their trials.
University of Erlangen-Nürnberg Medical School
Lead sponsor
Bavarian Cancer Research Center (BZKF)
Collaborator
University Hospital Augsburg
Collaborator
Ludwig-Maximilians - University of Munich
Collaborator
